GLP-1 drugs linked to heart risk worldwide

GLP-1 medications are increasingly discussed for more than weight loss, with NBC Connecticut highlighting potential benefits for fertility issues, PMOS, and endometriosis, alongside questions about how often patients should see doctors, ideally six to twelve times in the first year, though access can be difficult. Medical experts stress ongoing oversight to monitor weight changes, nutritional status, and possible side effects as patients’ bodies adapt to treatment. NGeneBio in Korea is venturing into genetic and blood tests to predict patient response to GLP-1 drugs and to monitor for pancreatic and biliary safety, applying sequencing and liquid biopsy tech from its cancer diagnostics work. The planned tests would examine variants in GLP1R and GIPR to gauge efficacy and risk, with monitoring assessing changes in blood methylation and circulating DNA. These developments occur amid a broader conversation about GLP-1 drugs fueling growth in obesity treatment while raising safety, access, and long-term use considerations. Collectively, the reporting underscores both the promise of GLP-1 therapies and the need for robust clinical guidance and monitoring.